Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Fandrick Keith R. 2. Date of Event Requiring Statement (Month/Day/Year) 10/08/2026 3. Issuer Name and Ticker or Trading Symbol IRulya Therapeutics Inc. [IRLA] (Last) (First) (Middle) C/O IRULYA THERAPEUTICS INC., 101 COLLEGE STREET, SUITE 210 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Operating Officer 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) NEW HAVEN, CT 06510 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	03/15/2036	Common Stock	30,442(2)	$1.81	D
Employee Stock Option (Right to Buy)	(3)	03/15/2036	Common Stock	5,626(4)	$1.81	D
Employee Stock Option (Right to Buy)	(1)	07/24/2027	Common Stock	173(5)	$1.81	D
Employee Stock Option (Right to Buy)	(1)	10/19/2030	Common Stock	208(6)	$1.81	D
Employee Stock Option (Right to Buy)	(1)	10/19/2030	Common Stock	69(7)	$1.81	D
Employee Stock Option (Right to Buy)	(1)	10/19/2030	Common Stock	104(8)	$1.8	D
Employee Stock Option (Right to Buy)	(1)	03/01/2031	Common Stock	34(9)	$1.84	D
Employee Stock Option (Right to Buy)	(1)	03/01/2031	Common Stock	138(10)	$1.81	D
Employee Stock Option (Right to Buy)	(1)	01/26/2032	Common Stock	346(11)	$1.81	D
Employee Stock Option (Right to Buy)	(1)	01/26/2033	Common Stock	1,213(12)	$1.81	D
Employee Stock Option (Right to Buy)	(1)	03/14/2034	Common Stock	5,278(13)	$1.81	D
Employee Stock Option (Right to Buy)	(1)	08/12/2034	Common Stock	3,026(14)	$1.81	D
Employee Stock Option (Right to Buy)	(15)	02/10/2035	Common Stock	2,774(16)	$1.8	D
Employee Stock Option (Right to Buy)	(1)	05/11/2036	Common Stock	92,168(17)	$16.81	D
Employee Stock Option (Right to Buy)	(18)	05/11/2036	Common Stock	92,168(17)	$16.81	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Fandrick Keith R. C/O IRULYA THERAPEUTICS INC. 101 COLLEGE STREET, SUITE 210 NEW HAVEN, CT 06510			Chief Operating Officer

Signatures

/s/ John Militello, Attorney-in-Fact		10/19/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Immediately exercisable.
(2)	Received in exchange for a stock option to acquire 608,856 shares of Orphai Therapeutics, LLC ("Orphai") common stock with an exercise price of $0.09 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the "Merger Agreement"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Orphai Holdings Therapeutics, Inc., a Delaware corporation ("HoldCo") and Orphai.
(3)	Beginning March 16, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Orphai's 2026 Stock Incentive Plan (the "2026 Plan")) wih the Issuer as of each such vesting date.
(4)	Received in exchange for stock options to acquire an aggregate of 112,537 shares of Orphai common stock with an exercise price of $0.09 per share pursuant to the Merger Agreement.
(5)	Received in exchange for stock options to acquire an aggregate of 3,467 shares of Orphai common stock with an exercise price of $0.09 per share pursuant to the Merger Agreement.
(6)	Received in exchange for stock options to acquire an aggregate of 4,161 shares of Orphai common stock with an exercise price of $0.09 per share pursuant to the Merger Agreement.
(7)	Received in exchange for stock options to acquire an aggregate of 1,387 shares of Orphai common stock with an exercise price of $0.09 per share pursuant to the Merger Agreement.
(8)	Received in exchange for stock options to acquire an aggregate of 2,080 shares of Orphai common stock with an exercise price of $0.09 per share pursuant to the Merger Agreement.
(9)	Received in exchange for stock options to acquire an aggregate of 693 shares of Orphai common stock with an exercise price of $0.09 per share pursuant to the Merger Agreement.
(10)	Received in exchange for stock options to acquire an aggregate of 2,774 shares of Orphai common stock with an exercise price of $0.09 per share pursuant to the Merger Agreement.
(11)	Received in exchange for stock options to acquire an aggregate of 6,935 shares of Orphai common stock with an exercise price of $0.09 per share pursuant to the Merger Agreement.
(12)	Received in exchange for stock options to acquire an aggregate of 24,272 shares of Orphai common stock with an exercise price of $0.09 per share pursuant to the Merger Agreement.
(13)	Received in exchange for stock options to acquire an aggregate of 105,577 shares of Orphai common stock with an exercise price of $0.09 per share pursuant to the Merger Agreement.
(14)	Received in exchange for stock options to acquire an aggregate of 60,522 shares of Orphai common stock with an exercise price of $0.09 per share pursuant to the Merger Agreement.
(15)	25% of the shares subject to the option vested on February 11, 2026 and the remaining shares vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the 2026 Plan) with the Issuer as of each such vesting date.
(16)	Received in exchange for stock options to acquire an aggregate of 55,480 shares of Orphai common stock with an exercise price of $0.09 per share pursuant to the Merger Agreement.
(17)	Received in exchange for stock options to acquire an aggregate of 1,843,370 shares of Orphai common stock with an exercise price of $0.84 per share pursuant to the Merger Agreement.
(18)	Beginning May 21, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the 2026 Plan) wih the Issuer as of each such vesting date.
Remarks: Exhibit 24 - Power of Attorney.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.